Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives
Authors:
- Mahsa BabaeiMBMahsa Babaei
- Mehran MiroliaeiMMMehran Miroliaei
Open Access
- 30 October 2026
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 204
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- Mucoadhesive TMC-coated solid lipid nanoparticles for oral co-delivery of docetaxel and curcumin: formulation optimization, in vitro characterization, and cytotoxic evaluation3 Biotech, 2026
- Ursolic acid as a multifunctional anticancer agent with insights into molecular mechanisms therapeutic potential and formulation strategiesDiscover Oncology, 2026
- Lupeol‐Loaded Liposomes: Triple‐Negative Breast Cancer (TNBC) Cytotoxicity and In Vivo Toxicological EvaluationChemistry & Biodiversity, 2025
- Celastrol-loaded ginsenoside Rg3 liposomes boost immunotherapy by remodeling obesity-related immunosuppressive tumor microenvironment in melanomaActa Pharmaceutica Sinica B, 2025
- Broad‐Spectrum Therapeutic Potentials of the Multifaceted Triterpene Lupeol and Its DerivativesChemistry & Biodiversity, 2025
- Oleanane-type triterpenoids from Sabia limoniacea and their anti-inflammatory activitiesBioorganic Chemistry, 2024
- Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of BiopharmaceuticalsAdvanced Materials, 2023
- Lipid Nanoparticles for Drug DeliveryAdvanced NanoBiomed Research, 2021
- In vitro co-delivery evaluation of PEGylated nano-liposome loaded by glycyrrhizic acid and cisplatin on cancer cell linesJournal of Nanoparticle Research, 2020
- Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and preventionAdvanced Drug Delivery Reviews, 2011